Amgen Announces 15 Percent Increase In 2018 First Quarter Dividend
THOUSAND OAKS, Calif., Dec. 12, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.32 per share dividend for the first quarter of 2018. The dividend will be paid on March 8, 2018, to all stockholders of record as of the close of business on Feb. 15, 2018. This represents a 15 percent increase from that paid in each of the previous four quarters.
About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by us...
Source: Amgen News Release - December 12, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
KYPROLIS ® (carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma In Phase 3 ASPIRE Trial
Results Highlighted During Oral Presentation at ASH 2017
Addition of KYPROLIS to Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone Alone
Regulatory Applications Submitted in the U.S. to add ASPIRE Overall Survival Results to KYPROLIS Label
THOUSAND OAKS, Calif., Dec. 11, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new results showing the positive overall survival (OS) findings from the final analysis of the Phase 3 ASPIRE trial. The study met the key secondary endpoint of OS, demonstrating that the addition of KYPROLIS® (carfilzomib) to len...
Source: Amgen News Release - December 11, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Foundation Pledges Up To $500,000 In Relief To Victims Of The Southern California Wildfires
Amgen Foundation Commits $200,000 to the United Way of Ventura County to Support Their Urgent Relief Efforts
THOUSAND OAKS, Calif., Dec. 11, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Amgen Foundation has pledged $500,000 to support victims of the Southern California wildfires. Of this commitment, $200,000 will be directed to the United Way of Ventura County to support their immediate relief efforts. The Foundation has also committed up to an additional $300,000 to support victims of the Southern California wildfires.
"These devastating fires have caused significant damage to our communities...
Source: Amgen News Release - December 11, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
New Data To Be Presented At ASH 2017 Underscore Amgen's Commitment To Improving Lives And Changing Outcomes For Patients With Difficult-To-Treat Blood Cancers
Positive Overall Survival Data From Phase 3 ASPIRE Trial on KYPROLIS® (Carfilzomib) in Relapsed Multiple Myeloma to be Highlighted in Oral Presentation
Results From Several Abstracts Highlight the Potential of Amgen's Bispecific T Cell Engager (BiTE®) Platform as an Innovative Approach to Treating Blood Cancers
FDA Grants Priority Review for BLINCYTO (Blinatumomab) Supplemental Biologics License Application in Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia
THOUSAND OAKS, Calif., Dec. 7, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new clinical data and analyses from 33 abstracts...
Source: Amgen News Release - December 7, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen To Webcast Investor Call At ASH 2017
THOUSAND OAKS, Calif., Dec. 6, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community at the 59th American Society of Hematology (ASH) Annual Meeting & Exposition on Saturday, Dec. 9, 2017, at 11:30 a.m. ET. David M. Reese, M.D., senior vice president of Translational Sciences and Oncology at Amgen, together with other members of Amgen's management team and a clinical investigator, will participate to discuss the Company's oncology program, including our BiTE® immunotherapy platform.
Live audio of the investor call will be simultaneously broadcast over the Internet and wil...
Source: Amgen News Release - December 6, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
FDA Approves Amgen's Repatha ® (evolocumab) To Prevent Heart Attack And Stroke
Following FDA Priority Review, Repatha is the Only PCSK9 Inhibitor Approved to Reduce Risk of Heart Attack, Stroke and Coronary Revascularization
THOUSAND OAKS, Calif., Dec. 1, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that following priority review of its supplemental Biologics License Application, the U.S. Food and Drug Administration (FDA) approved Repatha® (evolocumab) as the first PCSK9 inhibitor to prevent heart attacks, strokes and coronary revascularizations in adults with established cardiovascular disease.1
"We are pleased that the FDA made the inclusion of our outcomes data a priority ...
Source: Amgen News Release - December 1, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Aimovig ™ (erenumab) Phase 3 STRIVE Data Published In The New England Journal Of Medicine Demonstrate Significant, Sustained Efficacy In Migraine Prevention
Patients With Episodic Migraine Taking Aimovig Reported Significant and Meaningful Benefits Over Six Months, With Reduced Monthly Migraine Days and Acute Medication Use
Fifty Percent of Patients Taking Aimovig 140 mg Had Their Migraine Days Cut by at Least Half - Nearly Three-Fold Higher Odds Compared to Placebo
Patients Taking Aimovig Reported Reduced Physical Impairment and Improved Ability to Participate in Daily Activities Based on a Novel Patient-Reported Outcomes Tool
Ninety Percent of Patients Completed the Six-Month Study; Data Reinforce the Safety and Tolerability Profile of Aimovig Consistently Seen in the ...
Source: Amgen News Release - November 29, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
